"Leading Innovation in AI Drug Discovery"... Daewoong Pharmaceutical Selected as Research Institution for K-AI National Project

Development of Reverse Translational Research Design AI Model
Enhancing the Success Rate of Drug Discovery

Daewoong Pharmaceutical is participating as a key research partner in a government-led project to establish an artificial intelligence (AI) drug discovery platform, taking the lead in creating a next-generation environment for new drug development.

On November 17, Daewoong Pharmaceutical announced that it has been selected as a joint research institution for the "2025 K-AI Preclinical and Clinical Model Development Project for Drug Discovery," overseen by the Ministry of Health and Welfare.

Daewoong Pharmaceutical Yongin Research Center exterior. Daewoong Pharmaceutical

This project is part of efforts to build a comprehensive domestic ecosystem for drug discovery based on artificial intelligence (AI). Daewoong Pharmaceutical will participate in the development of "reverse translational research design AI software (AI SW)." The project is led by Samsung Medical Center and will operate as a multi-institutional joint research system involving hospitals and pharmaceutical companies, including Kangbuk Samsung Hospital and Daewoong Pharmaceutical.

The goal of the project is to develop an AI model capable of integrated analysis of preclinical and clinical data based on "reverse translational research." This approach supplements preclinical research design with clinical data, thereby reducing trial and error and increasing the likelihood of success in the drug development process.

Over the next four years, Daewoong Pharmaceutical will provide non-clinical data obtained from research on oncology and metabolic diseases for AI model development. In addition, the company plans to use research data generated at its New Drug Center to conduct demonstration projects that apply the developed AI software to actual research.

Through this project, Daewoong Pharmaceutical aims to utilize AI to more precisely design animal experiment models and to secure technological capabilities for predicting clinical outcomes based on non-clinical data. The company also intends to use the project to build and further advance AI models tailored to its own research projects.

Furthermore, leveraging AI models and data focused on oncology and metabolic diseases, Daewoong Pharmaceutical plans to establish a universal clinical AI platform that can be expanded to various disease areas, thereby accelerating the expansion of its new drug pipeline.

Park Sungsoo, CEO of Daewoong Pharmaceutical, stated, "By participating in the actual model development, we can experience the advancement of AI technology firsthand in the research field, which will serve as an opportunity to further elevate Daewoong Pharmaceutical's research and development capabilities. We are committed to contributing to the creation of an innovative AI-based drug discovery ecosystem."

This content was produced with the assistance of AI translation services.